Plus Therapeutics股价上涨，因其旗下子公司与Elevance Health就癌症检测达成协议

路透中文06-25 19:45
BUZZ-Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a>股价上涨，因其旗下子公司与<a href="https://laohu8.com/S/ELV">Elevance Health</a>就癌症检测达成协议

6月25日 - ** 生物技术公司 Plus Therapeutics（PSTV.O）的股价在盘前交易中上涨 2.8%，至 4.07 美元

** 该公司表示，其旗下CNSide Diagnostics部门已与Elevance Health签署了一项全国性协议，以扩大其脑脊液肿瘤检测服务的覆盖范围

** 该检测有助于发现已扩散至大脑和脊髓的癌症，这种严重病症被称为中枢神经系统转移

** 该协议将覆盖约4,540万人，使签约覆盖总人数达到1.26亿

** 据称，自2020年以来，该检测已在美国120多家癌症中心被使用超过11,000次

** 据Plus Therapeutics称，约90%的病例中，检测结果影响了治疗决策

** 截至上一交易日收盘，该股年内累计跌幅约为69%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment